OncoZenge rights issue ~92% subscribed; raises ~SEK 30.7M

OncoZenge’s rights issue is preliminarily ~92% subscribed: 80% with rights and 12% without. Expected gross proceeds are ~SEK 30.7M, and the Vator Securities AB guarantee is not expected to be utilised.